NEW YORK (360Dx) – Accelerate Diagnostics reported after the market closed on Thursday that its preliminary third quarter revenues increased sharply, but still fell far short of the consensus Wall Street estimate.

For the three months ended Sept. 30, the company posted revenues of $828,000, up from $24,000 in Q3 2016, driven by further sales of the Accelerate Pheno system and Accelerate PhenoTest BC kit. The preliminary revenues would miss the analysts’ average estimate of $2.6 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.